Advertisement

Topics

Incorporating Precision Medicine Into the Treatment of NSCLC

07:14 EDT 23 Jun 2017 | OncoTherapy Network

Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.

Original Article: Incorporating Precision Medicine Into the Treatment of NSCLC

NEXT ARTICLE

More From BioPortfolio on "Incorporating Precision Medicine Into the Treatment of NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...